Bilfinger SE

  • WKN: 590900
  • ISIN: DE0005909006
  • Land: Deutschland

Nachricht vom 20.08.2021 | 11:41

Bilfinger SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Bilfinger SE / Preliminary announcement on the disclosure of financial statements
20.08.2021 / 11:41
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Bilfinger SE hereby announces that the following financial reports shall be disclosed:

Report Type: Annual financial report

Language: German
Date of disclosure: March 10, 2022
Address: http://www.bilfinger.com/Jahresfinanzbericht_SE_2021

Language: English
Date of disclosure: March 10, 2022
Address: http://www.bilfinger.com/en/Annual_Financial_Statements_SE_2021

Report Type: Annual financial report of the group

Language: German
Date of disclosure: March 10, 2022
Address: http://www.bilfinger.com/Geschaeftsbericht_2021

Language: English
Date of disclosure: March 10, 2022
Address: http://www.bilfinger.com/en/Annual_Report_2021

Report Type: Financial report of the group (half-year/Q2)

Language: German
Date of disclosure: August 11, 2022
Address: http://www.bilfinger.com/Zwischenbericht_2022

Language: English
Date of disclosure: August 11, 2022
Address: http://www.bilfinger.com/en/Interim_Report_2022


20.08.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021